Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

81. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society

Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 21, No. 10, pp. 1063/1068 DOI: 10.1097/gme.0000000000000329 * 2014 by the European Menopause and Andropause Society, International Menopause Society, International Society for the Study of Women’s Sexual Health and The North American (...) Menopause Society SPECIAL FEATURE Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women_s Sexual Health and The North American Menopause Society David J. Portman, MD, 1 Margery L.S. Gass, MD, NCMP, 2 on behalf of the Vulvovaginal Atrophy Terminology Consensus Conference Panel Abstract Background: In 2012, the Board of Directors of the International Society for the Study of Women’s Sexual Health(ISSWSH

2014 The North American Menopause Society

82. Menopause Chapter 5: Clinical Evaluation and Counseling

Menopause Chapter 5: Clinical Evaluation and Counseling Chapter 5: Clinical Evaluation and Counseling | | | | Chapter 5: Clinical Evaluation and Counseling > > > HISTORY AND PHYSICAL EXAM Key Points The health evaluation at the time of the menopause transition should be tailored to the individual woman based on her medical, social, and family history, as well as on her symptoms and quality-of-life goals. Sexual and psychological histories are an important part of the assessment of women during (...) the menopause transition. The evidence supporting various aspects of the physical exam, including the clinical breast exam and bimanual pelvic exam, is limited and contradictory. Recommendations for Clinical Care A thorough history and focused physical exam can guide clinicians and their patients in managing the symptoms of the menopause transition and providing guidance to support enhanced health for women as they age. (Level II) The evaluation and counseling of a midlife woman should be individualized

2014 The North American Menopause Society

83. Menopause Chapter 2: Midlife Body Changes

Menopause Chapter 2: Midlife Body Changes Chapter 2: Midlife Body Changes | | | | Chapter 2: Midlife Body Changes > > > VULVOVAGINAL CHANGES Key Points Postmenopausal estrogen loss and aging accompanied by physiologic, vascular, neurologic, and histologic changes may result in vulvovaginal symptoms, including irritation, burning, itching, vaginal discharge, postcoital bleeding, and dyspareunia. Genitourinary syndrome of menopause (GSM), a syndrome that encompasses symptomatic vulvovaginal (...) atrophy (VVA), may have a significant impact on the quality of life of midlife women, with effects on sexual function and interpersonal relationships. Women of any age with low estrogen levels, including women with primary ovarian insufficiency, premature menopause, hypothalamic amenorrhea, or hyperprolactinemia; during lactation; or after treatment with gonadotropin-releasing hormone (GnRH) agonists/antagonists or aromatase inhibitors, may experience symptoms of GSM/VVA. The presentation, diagnosis

2014 The North American Menopause Society

84. Chapter 1: Menopause

Chapter 1: Menopause Chapter 1: Menopause | | | | Chapter 1: Menopause > > > OVERVIEW OF MENOPAUSE Key Points Menopause is a normal physiologic event, defined as the final menstrual period (FMP) and reflecting loss of ovarian follicular function. Spontaneous or natural menopause is recognized retrospectively after 12 months of amenorrhea. It occurs at an average age of 52 years, but the age of natural menopause can vary widely from 40 to 58 years. Induced menopause refers to the cessation (...) of menstruation that occurs after either bilateral oophorectomy or iatrogenic ablation of ovarian function (eg, by chemotherapy or pelvic radiation). The Stages of Reproductive Aging Workshop (STRAW) established a nomenclature and a staging system for the female reproductive aging continuum in 2001, which was revised in 2011 with the STRAW + 10 staging system. According to STRAW + 10, the term menopause transition refers to the span of time when menstrual cycle and endocrine changes occur, beginning

2014 The North American Menopause Society

85. Menopause Chapter 4: Disease Risk

Menopause Chapter 4: Disease Risk Chapter 4: Disease Risk | | | | Chapter 4: Disease Risk > > > CARDIOVASCULAR HEALTH Key Points Cardiovascular disease (CVD) is the leading cause of death in women worldwide. Major risk factors for CVD in women include age, hypertension, dyslipidemia, diabetes mellitus (DM), family history of premature CVD, smoking, sedentary lifestyle, and poor diet. Novel risk factors for CVD include a history of a pregnancy complicated by preeclampsia, gestational diabetes (...) , or hypertension. Hormonal changes associated with menopause can result in an accelerated increase in low-density lipoprotein cholesterol (LDL-C) in the year following menopause. Recommendations for Clinical Care All women should be encouraged to reduce their risk for CVD, including heart attack and stroke, by engaging in regular exercise, consuming a healthy diet, achieving a normal body weight, and not smoking. Healthcare providers should evaluate all women for CVD risk using the American College

2014 The North American Menopause Society

86. Menopause Chapter 3: Clinical Issues

Menopause Chapter 3: Clinical Issues Chapter 3: Clinical Issues | | | | Chapter 3: Clinical Issues > > > DECLINE IN FERTILITY Key Points Fertility declines with increasing age, notably after age 35 years, or approximately 15 years before menopause. Age-related declines in fertility have been confirmed in epidemiologic studies as well as by the observation of declining pregnancy rates with advancing age in cycles of donor insemination and in vitro fertilization (IVF). Advanced maternal age (≥35 (...) . (Level II) In older women undergoing oocyte-donation IVF, single-embryo transfer should be strongly considered because of the risks associated with multiple births. (Level II) Women of advancing age considering donor-oocyte IVF should be counseled about parenting issues and health concerns specific to their age and the age and health of their partner. (Level II) UTERINE BLEEDING Key Points Approximately 90% of women experience 4 to 8 years of menstrual cycle changes before natural menopause, which

2014 The North American Menopause Society

87. Management of Menopausal Symptoms

Management of Menopausal Symptoms Sign In (ACOG) Sign in to your ACOG account Email is required. Please enter valid Email. was not found in our system. Would you like to associated with your account? Forgot your email address? JSOG Member? © 2019 - American College of Obstetricians and Gynecologists

2014 American College of Obstetricians and Gynecologists

88. Bone Densitometry testing for menopausal women aged 50

Bone Densitometry testing for menopausal women aged 50 Ap ene Spons Date o Context at www 1. An appl women The app spine bo stage, id individu would b 2. After co effectiv 50 year ? ? 3. MSAC and lum year in risk and pplicatio ergy X-ra sor/Applica of MSAC c t for decisio w.msac.gov. Purpose o lication req in their 50 t plication pro one densito dentifying i uals with a n be given app MSAC’s a onsidering t veness, MSA rs. This was There was n assessment Currently M Summary noted that t mbar (...) , this target population would not have a combination of risk factors (eg being female and peri-menopausal) that would sufficiently differentiate the requested testing arrangements from a primary health screening service given that they are otherwise healthy. In this regard, MSAC noted that Section 19 (5) of the Health Insurance Act 1973 generally prevents payment of Medicare benefits for screening services stating: "Unless the Minister otherwise directs, a Medicare benefit is not payable in respect

2014 Medical Services Advisory Committee

89. Randomised controlled trial: Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase

Randomised controlled trial: Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Menopausal hormone therapy has risks and benefits during the intervention and poststopping phase Article Text Prevention Randomised controlled trial Menopausal hormone

2014 Evidence-Based Medicine

90. Oral progesterone for the treatment of menopausal symptoms: clinical evidence

Oral progesterone for the treatment of menopausal symptoms: clinical evidence Oral progesterone for the treatment of menopausal symptoms: clinical evidence Oral progesterone for the treatment of menopausal symptoms: clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Oral progesterone for the treatment (...) of menopausal symptoms: clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One systematic review, 23 publications from randomized controlled trials, and two non-randomized studies were identified regarding the clinical efficacy of micronized progesterone or medroxyprogesterone, or the comparative clinical efficacy of micronized progesterone versus medroxyprogesterone, for the management of menopausal symptoms. Final publication

2014 Health Technology Assessment (HTA) Database.

91. Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence

Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) CADTH. Oral progesterone for the treatment of menopausal symptoms: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Conjugated equine estrogens plus medroxyprogesterone (MPA) did not increase the risk of developing atrial fibrillation, increased the risk of invasive breast cancer, and increased the incidence of deaths attributed to lung cancer compared to placebo in the Women's Health Initiative study

2014 Health Technology Assessment (HTA) Database.

92. Salivary hormone testing for menopausal women

Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Salivary hormone testing for menopausal women Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Salivary hormone testing for menopausal women. Lansdale: HAYES, Inc.. Directory Publication. 2013 Authors' conclusions Salivary hormone testing (SHT) is used to measure levels (...) of hormones, including estrogens, progestogens, androgens, and cortisol. Compared with hormone testing in blood, salivary hormone testing is noninvasive and saliva can be collected by patients at home. Salivary hormone testing is often recommended for women who receive hormone replacement therapy, especially women who receive compounded hormone preparations. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Female; Hormones; Humans; Menopause

2013 Health Technology Assessment (HTA) Database.

93. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Full Text available with Trip Pro

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention.To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention follow-up.A total of 27,347 postmenopausal women

2013 JAMA Controlled trial quality: predicted high

94. Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women

Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women UTCAT2545, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Morphology of Mandibular Inferior Cortex in Panoramic Radiograph Can Help Diagnose Osteoporosis in Post Menopausal Women Clinical Question In postmenopausal women can the morphology of the mandibular inferior cortex be used as a screening (...) postmenopausal women (Group A) and 157 Post Menopausal women with histories of hysterectomy, oophorectomy, or estrogen use (Group B). Subjects had a diagnostic performances of panoramic measurements, Bone Mineral Density (BMD) at the lumber Spine (L2-L4) was measured by Dual –Energy X-ray Absorptiometry In vivo study Clinical trial Key results Dual Energy X ray Absorptiometry (DXA) of the Lumbar Spines (Bone Mineral Density) is the Gold Standard for Diagnosing Osteoporosis. Study group was categorized into 3

2013 UTHSCSA Dental School CAT Library

95. Bioidentical hormone replacement therapy for menopausal symptoms

Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Bioidentical hormone replacement therapy for menopausal symptoms Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Bioidentical hormone replacement therapy for menopausal symptoms. Lansdale: HAYES, Inc.. Directory Publication. 2013 (...) Authors' conclusions Bioidentical hormone replacement therapy (BHRT) includes both "natural", compounded hormones obtained from compounding pharmacies and Food and Drug Administration-approved hormones that are identical to endogenous hormones. BHRT is used to treat the symptoms of menopause, including: vasomotor symptoms, urogenital symptoms, and bone loss. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Hormone Replacement Therapys

2013 Health Technology Assessment (HTA) Database.

96. Abnormal Uterine Bleeding in Pre-Menopausal Women

Abnormal Uterine Bleeding in Pre-Menopausal Women 404 Toggle navigation Toggle search Keyword search language Keyword search 404 Error Page/Asset Not Found The Society of Obstetricians and Gynaecologists of Canada (SOGC) {1} {1} {1}

2013 Society of Obstetricians and Gynaecologists of Canada

97. Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause

Osphena (ospemifene) - To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Osphena (ospemifene) Oral Tablets Company: Shionogi Inc. Application No.: 203505 Approval Date: 2/26/2013 Persons with disabilities having problems accessing the PDF files below may

2013 FDA - Drug Approval Package

98. Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause

Duavee (conjugated estrogens / bazedoxifene) - To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause Drug Approval Package: Duavee NDA #022247 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Duavee (conjugated estrogens and bazedoxifene) Company: Wyeth Pharmaceuticals, Inc. Application No.: 022247 Approval Date: 10/3/2013 Persons with disabilities having problems accessing

2013 FDA - Drug Approval Package

99. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society

Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Menopause: The Journal of The North American Menopause Society Vol. 20, No. 9, pp. 888/902 DOI: 10.1097/gme.0b013e3182a122c2 * 2013 by The North American Menopause Society POSITION STATEMENT Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society Abstract Objective: To update and expand the previous position statement (...) of The North American Menopause Society (NAMS) on the management of symptomatic vulvovaginal atrophy (VVA) in postmenopausal women. Methods:NAMSsearchedPubMedformedicalliteratureonVVApublishedsincetheir2007positionstatement on the role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women. A panel of ac- knowledged experts in the field of genitourinary health reviewed the literature to evaluate new evidence on local estrogen as well as on other management options available

2013 The North American Menopause Society

100. Global Consensus Statement on Menopausal Hormone Therapy

Global Consensus Statement on Menopausal Hormone Therapy CLIMACTERIC 2013;16:203–204 © 2013 International Menopause Society and Elsevier Inc. DOI: 10.3109/13697137.2013.771520 This Statement is being simultaneously published in the journals Climacteric and Maturitas , on behalf of the International Menopause Society and The European Menopause and Andropause Society, respectively. Correspondence: T. J. de Villiers, MediClinic Panorama, Parow 7500, South Africa Global Consensus Statement (...) on Menopausal Hormone Therapy T. J. de Villiers , M. L. S. Gass * , C. J. Haines † , J. E. Hall ‡ , R. A. Lobo * * , D. D. Pierroz † † and M. Rees ‡ ‡ MediClinic Panorama and Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa; * Department of Surgery, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH, USA; † Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Prince of Wales

2013 The North American Menopause Society